ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0481

Hyperkalemia, CKD, and RAAS Inhibition: A Triad with a Fine Balance to Prevent Mortality

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Goncalves, Luis Falcao, Hospital Beatriz Angelo, Loures, Lisboa, Portugal
  • Raimundo, Mario Rui, Hospital Beatriz Angelo, Loures, Lisboa, Portugal
Background

Hyperkalemia (HK) is a common and dangerous complication of CKD. HK is also a complication of beneficial therapeutic agents acting on the RAAS. Our goal was to investigate incidence, prevalence and clinical outcomes of at least one episode of HK in a CKD population outpatient setting. Additionally, we investigated the association of HK with changes in RAAS inhibition and mortality risk.

Methods

Retrospective analysis of all adult patients referred to a nephrology clinic over a 6 years period. We included CKD stage 3 patients with at least 24 months of follow up and 3 or more serum potassium determinations. The prevalence of HK at first consultation and incidence during follow up were accessed. Patients were spited in two groups prior to analysis: A) Patients without any HK episode and B) Patients with at least one HK episode.

Results

Out of the 3008 patients referred, 575 (19.1%) met the inclusion criteria (mean age: 70.4 years; 63.7% male and 94.0% white color). Mean follow-up was 4.1±1.8 years. The prevalence of HK at first consultation was 8.7% and follow up incidence 21.7%. From this cohort, 164 (28.5%) had at least on episode of HK (Group B) and 101 (17.6%) died. During the follow up, RAAS inhibition drugs was removed or not started in 200 (34.8%) and diuretic was initiated in 165 (28.7%). At least one HK episode was associated with Diabetes (65.9 vs 42.3%, p<0.001), Heart failure (36.6 vs 28.0%, p=0.007), Macroalbuminuria (34.1 vs 21.2%, p=0.001), CKD progression (33.5 vs 16.3. p<0.001) higher frequency of diuretic initiation (38.4 vs 24.8%, p<0.001) and higher mortality (27.6 vs 13.7%, p<0.001).
The independent predictors of mortality were: At least one HK episode (OR 1.82, 95% CI 1.08-3.04); Heart Failure (OR 1.97, 95% CI 1.16-3.35); Older age (OR per 1 year increase 1.04, 95% CI 1.02-1.07); CKD progression (OR 4.18, 95% CI 2.43-7.19); Patients who maintained RAAS inhibition during follow up (OR 0.50, 95% CI 0.26-0.96); Patients who started RAAS inhibition during follow up (OR 0.38, 95% CI 0.16-0.88).

Conclusion

Our study confirms that RAAS inhibition had and protector and independent impact in mortality when prescribed in CKD early stages. Patients with at least one episode of HK have a higher risk of mortality. All efforts should be made to maintain these therapeutic agents, looking for other ways to control hyperkalemia rather than stop it.